Naoki Kumashiro

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 12

Top Topics

Magnetic Resonance

Cardiovascular Risk Factors

Sentinel Lymph Node

Top Venues

Diabetes, obesity & metabolism

Cardiovascular diabetology

Journal of diabetes investigation

Diabetes therapy : research, treatment and education of diabetes and related disorders

This page only lists publications with an associated author ORCID identifier.

Publications

Shigenori Hiruma, Fumika Shigiyama, Naoki Kumashiro
Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue-specific insulin sensitivity in patients with early-stage type 2 diabetes with non-alcoholic fatty liver disease: A prospective randomized study. Diabetes, obesity & metabolism (2023)
Kota Takuma, Ayako Fuchigami, Fumika Shigiyama, Naoki Kumashiro, Takahisa Hirose
Comparison of the effects of sitagliptin and dapagliflozin on time in range in Japanese patients with type 2 diabetes stratified by body mass index: A sub-analysis of the DIVERSITY-CVR study. Diabetes, obesity & metabolism (2023)
Shigenori Hiruma, Fumika Shigiyama, Naoki Kumashiro
Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue-specific insulin sensitivity in patients with early-stage type 2 diabetes with nonalcoholic fatty liver disease: A prospective randomized study. Diabetes, obesity & metabolism (2023)
Shigenori Hiruma, Fumika Shigiyama, Shinji Hisatake, Sunao Mizumura, Nobuyuki Shiraga, Masaaki Hori, Takanori Ikeda, Takahisa Hirose, Naoki Kumashiro
A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study. Cardiovascular diabetology 20 (1) (2021)
Yasuyo Ando, Fumika Shigiyama, Takahisa Hirose, Naoki Kumashiro
Simplification of complex insulin regimens using canagliflozin or liraglutide in patients with well-controlled type 2 diabetes: A 24-week randomized controlled trial. Journal of diabetes investigation 12 (10) (2021)
Ayako Fuchigami, Fumika Shigiyama, Toru Kitazawa, Yosuke Okada, Takamasa Ichijo, Mariko Higa, Toru Hiyoshi, Ikuo Inoue, Kaoru Iso, Hidenori Yoshii, Takahisa Hirose, Naoki Kumashiro
Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR). Cardiovascular diabetology 19 (1) (2020)
Fumika Shigiyama, Shigenori Hiruma, Shinji Hisatake, Nobuyuki Shiraga, Takanori Ikeda, Takahisa Hirose, Naoki Kumashiro
Rationale, Design for the ASSET Study: A Prospective Randomized Study Comparing Empagliflozin's Effect to Sitagliptin on Cardiac Fat Accumulation/Function in Patients with Type 2 Diabetes. Diabetes therapy : research, treatment and education of diabetes and related disorders 10 (4) (2019)
Hiroyuki Igarashi, Fumika Shigiyama, Noritaka Wakui, Hidenari Nagai, Kazutoshi Shibuya, Nobuyuki Shiraga, Takahisa Hirose, Naoki Kumashiro
Whole hepatic lipid volume quantification and color mapping by multi-slice and multi-point magnetic resonance imaging. Hepatology research : the official journal of the Japan Society of Hepatology 49 (12) (2019)
Fumika Shigiyama, Naoki Kumashiro, Ayako Fuchigami, Takahisa Hirose
Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study. Cardiovascular diabetology 17 (1) (2018)
Fumika Shigiyama, Naoki Kumashiro, Yousuke Tsuneoka, Hiroyuki Igarashi, Fukumi Yoshikawa, Saori Kakehi, Hiromasa Funato, Takahisa Hirose
Mechanisms of sleep deprivation-induced hepatic steatosis and insulin resistance in mice. American journal of physiology. Endocrinology and metabolism 315 (5) (2018)
Fukumi Yoshikawa, Naoki Kumashiro, Fumika Shigiyama, Hiroshi Uchino, Yasuyo Ando, Hiroshi Yoshino, Masahiko Miyagi, Kayoko Ikehara, Takahisa Hirose
Efficacy of intermittent empagliflozin supplementation on dietary self-management and glycaemic control in patients with poorly controlled type 2 diabetes: A 24-week randomized controlled trial. Diabetes, obesity & metabolism 21 (2) (2018)
Fumika Shigiyama, Naoki Kumashiro, Masahiko Miyagi, Kayoko Ikehara, Eiichiro Kanda, Hiroshi Uchino, Takahisa Hirose
Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study. Cardiovascular diabetology 16 (1) (2017)